sitagliptin 100 mg Januvia
1 INDICATIONS AND USAGE JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes ( 1 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1 , 5.1 ) Limitations of Use JANUVIA should not be used in patients with type 1 diabetes. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA. [See Warnings and Precautions (5.1) .]
Merck Sharp & Dohme Corp.
ROUND BROWN 277
277 ROUND BROWN
Related Pills
sitagliptin 50 mg Januvia
merck sharp & dohme corp.
sitagliptin 25 mg Januvia
merck sharp & dohme corp.
hydroxyzine hydrochloride tablet film coated
glenmark pharmaceuticals inc., usa
hydroxyzine hydrochloride tablet film coated
glenmark pharmaceuticals inc., usa
aspirin delayed release aspirin tablet delayed release
time-cap labs, inc
dexmethylphenidate hydrochloride 10 MG Oral Tablet
Teva Pharmaceuticals USA, Inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Tablets are supplied as follows: Contents Description How Supplied NDC 25 mg
SITAGLIPTIN pink, round, film-coated tablets with “221” on one side Unit-of-use bottles of 30 Unit-of-use bottles of 90 Unit dose blister package of 100 NDC 0006-0221-31 NDC 0006-0221-54 NDC 0006-0221-28 50 mg
SITAGLIPTIN light beige, round, film-coated tablets with “112” on one side unit-of-use bottles of 30 unit-of-use bottles of 90 unit dose blister packages of 100 NDC 0006-0112-31 NDC 0006-0112-54 NDC 0006-0112-28 100 mg
SITAGLIPTIN beige, round, film-coated tablets with “277” on one side unit-of-use bottles of 30 unit-of-use bottles of 90 unit-of-use blister calendar package of 30 unit-of-use blister calendar package of 30 unit dose blister packages of 100 bottles of 1000. NDC 0006-0277-31 NDC 0006-0277-54 NDC 0006-0277-02 NDC 0006-0277-33 NDC 0006-0277-28 NDC 0006-0277-82 Storage Store at 20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature.]
More pills like ROUND 277